Overview

High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of pancreatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shenzhen Hank Bioengineering Institute